The objective of this Phase II study is to show that pre-treated patients with BEB with the
need of shortened injection intervals achieve an improved and stable quality of life level if
they receive repeated NT 201 injections at short injection intervals. In addition, the
tolerability of repeated shortened NT 201 administrations in patients with BEB including the
development of neutralizing antibodies will be investigated.
Phase:
Phase 2
Details
Lead Sponsor:
Merz Pharmaceuticals GmbH
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA